Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes

Obstetrics and Gynecology

Volumn 124, Issue 3, 2014, Pages 600-609

  Bergendal, Annica ^a   Persson, Ingemar ^a   Odeberg, Jacob ^a   Sundström, Anders ^a   Holmström, Margareta ^a   Schulman, Sam ^a   Björgell, Ola ^a   Kieler, Helle ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; DESOGESTREL; DNA; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS LYNESTRENOL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETHINYLESTRADIOL PLUS NORETHISTERONE; ETHINYLESTRADIOL PLUS NORGESTIMATE; ETONOGESTREL; GESTAGEN; LEVONORGESTREL; LYNESTRENOL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; BLOOD CLOTTING FACTOR 5; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BODY MASS; CASE CONTROL STUDY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DNA DETERMINATION; FEMALE; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HORMONAL CONTRACEPTION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; OBESITY; PLASTER CAST; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SWEDEN; TELEPHONE INTERVIEW; THROMBOPHILIA; VENOUS THROMBOEMBOLISM; COMPLICATION; CONTRACEPTION; GENETICS; MIDDLE AGED; POINT MUTATION; PROCEDURES; RISK FACTOR;

ADULT; BODY MASS INDEX; CONTRACEPTION; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, HORMONAL; DESOGESTREL; FACTOR V; FEMALE; HUMANS; MIDDLE AGED; POINT MUTATION; PROGESTINS; RISK ASSESSMENT; RISK FACTORS; SMOKING; SWEDEN; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

EID: 84925546158     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000000411     Document Type: Article

References (32)

1. Shapiro S, Dinger J. Risk of venous thromboembolism among users of oral contraceptives: a review of two recently published studies. J Farn Plann Reprod Health Care 2010; 36:33-8.
2. Dinger J, Shapiro S. Combined oral contraceptives, venous thromboembolism, and the problem of interpreting large but incomplete datasets. J Fam Plann Reprod Health Care 2012; 38:2-6.
3. Martínez F., Ramírez I, Pérez-Campos E, Latorre K, Lete I. Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis. Eur J Contracept Reprod Health Care 2012; 17:7-29.
4. Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009; 339:b2890.
5. Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Lokkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011; 343:d6423.
6. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009; 339:b2921.
7. Grimes DA, Stuart GS, Levi EE Screening women for oral contraception: can family history identify inherited thrombophilias? Obstet Gynecol 2012; 120:889-95.
8. Dayan N, Holcroft CA, Tagalakis V. The risk of venous thrombosis, including cerebral vein thrombosis, among women with thrombophilia and oral contraceptive use: a meta-analysis. Clin Appl Thromb Hemost 2011; 17:E141-52.
9. van Hylckama Vlieg A, Middeldorp S. Hormone therapies and venous thromboembolism: where are we now? J Thromb Haemost 2011; 9:257-66.
10. van Vlijmen E.F., Veeger NJ, Middeldorp S, Hamulyák K, Prins M.H., Büller HR, et al. Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception. Blood 2011; 118:2055-61.
11. van Sluis G.L., Söhne M, El Kheir DY, Tanck MW, Gerdes VE, Büller HR. Family history and inherited thrombophilia. J Thromb Haemost 2006; 4:2182-7.
12. Bergendal A, Odlind V, Persson I., Kieler H. Limited knowledge on progestogen-only contraception and risk of venous thromboembolism. Acta Obstet Gynecol Scand 2009; 88:261-6.
13. Bianco-Molina M.A., Lozano M, Cano A., Cristobal I, Pallardo LP, Lete I. Progestin-only contraception and venous thromboembolism. Thromb Res 2012; 129:e257-62.
14. Mantha S, Karp R Raghavan V, Terrin N, Bauer KA, Zwicker JI. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ 2012; 345:e4944.
15. Bergendal A Bremme K, Hedenmalm K, Lärfars G, Odeberg J, Persson I, et al. Risk factors for venous thromboembolism in preand postmenopausal women. Thromb Res 2012; 130:596-601.
16. World Health Organization. Technical report series 894: obesity: preventing and managing the global epidemic. Geneva (Switzerland): World Health Organization; 2000. Available at: http://whqlibdoc.who.int/trs/WHO-TRS-894-(partl).pdf. Retrieved July 7, 2014.
17. Ronaghi M, Uhlén M, Nyrén P. A sequencing method based on real-time pyrophosphate. Science 1998; 281:363, 365.
18. Lidegaard O, Nielsen LH, Skovlund C.W., Løkkegaard E. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10. BMJ 2012; 344:e2990.
19. Suissa S, Biais L, Spitzer W.O., Cusson J., Lewis M, Heinemann L First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997; 56:141-6.
20. Dinger JC, Heinemann LA, Kühl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 2007; 75:344-54.
21. Lijfering WM, Brouwer JL, Veeger N.J., Bank I., Coppens M, Middeldorp S, et al Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood 2009; 113:5314-22.
22. Martinelli I, Taioli E, Bucciarelli P., Akhavan S, Mannucci PM. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol 1999; 19:700-3.
23. Legnani C, Palareti G, Guazzaloca G., Cosmi B, Lunghi B, Bernardi F., et al. Venous thromboembolism in young women; role of thrombophilic mutations and oral contraceptive use. Eur Heart J 2002; 23:984-90.
24. Vandenbroucke JP, Koster T, Briët E, Reitsma P.H., Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344:1453-7.
25. Wu O, Robertson L, Langhorne P., Twaddle S, Lowe GD, Clark P, et al Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost 2005; 94:17-25.
26. Ravin AJ, Edwards RP, Krohn M, Kelley JR Christopherson WA, Roberts JM. The factor V Leiden mutation and the risk of venous thromboembolism in gynecologic oncology patients. Obstet Gynecol 2002; 100:1285-9.
27. van Rooijen M., Silveira A, Thomassen S., Hansson LO, Rosing J, Hamsten A, et al Rapid activation of haemostasis after hormonal emergency contraception. Thromb Haemost 2007; 97:15-20.
28. Vasilakis C, Jick H, del Mar Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet 1999; 354:1610-1.
29. van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol 2010; 30:2297-300.
30. World Health Organization. Medical eligibility criteria for contraceptive use. 4th ed. Geneva (Switzerland): World Health Organization; 2009.
31. Vessey M, Mant D, Smith A., Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study. Br Med J (Clin Res Ed) 1986; 292:526.
32. Stegeman BH, de Bastos M, Rosendaal FR van Hylckama Vlieg A Helmerhorst FM, Stijnen T, et al. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ 2013; 347:f5298.